Skip to main content
Top
Published in: Clinical Rheumatology 9/2007

01-09-2007 | Original Article

Early ultrasonographic markers of atherosclerosis in patients with familial Mediterranean fever

Authors: Ismail Sari, Oguzhan Karaoglu, Gercek Can, Servet Akar, Aytac Gulcu, Merih Birlik, Nurullah Akkoc, Mehmet Tunca, Yigit Goktay, Fatos Onen

Published in: Clinical Rheumatology | Issue 9/2007

Login to get access

Abstract

Systemic inflammation plays an important role in the development of atherosclerosis (AS). The aim of this study was to evaluate the presence of early AS in patients with familial Mediterranean fever (FMF) that is characterized by recurrent inflammatory attacks of serositis. Sixty-one FMF patients (30 Male/31 Female; 31.5 [18–54] years) and 31 healthy controls (16 Male/15 Female; 31 [22–58] years) were studied. All FMF patients were on regular daily colchicine treatment and during attack-free periods. Both the FMF patients and controls with a history of diabetes mellitus (DM), hypertension, and hyperlipidemia were excluded. Body mass index (BMI) was calculated. Serum lipids, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were assessed. Two-hour oral glucose tolerance test was performed to rule out DM and glucose intolerance. To investigate early AS “endothelium-dependent flow-mediated dilatation (FMD%),” “nitroglycerin-induced endothelium-independent peripheral vasodilatation (NTG%),” and intima-media thickness (IMT) of common carotid arteries (CCA) were measured by ultrasonograpy. The median disease duration for FMF patients was 16 (1–45) years. Age, sex, BMI, smoking status, and serum lipids were comparable in patients and controls (p > 0.05). However, ESR and standard CRP were significantly higher in the patients group (p < 0.05). There were no differences in the measurements of right, left, and averaged IMT of CCA between patients and controls ([0.49 vs 0.5], [0.51 vs 0.52] and [0.5 vs 0.51]; p > 0.05, respectively). None of the subjects had carotid artery plaques. FMD% and NTG% were also similar in patients and controls group ([18.2 vs 20.6] and [24.2 vs 22.5]; p > 0.05, respectively). This study suggests that the markers of early AS are not impaired in FMF patients on regular daily colchicine treatment.
Literature
1.
go back to reference Sohar E, Gafni J, Pras M, Heller H (1967) Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 43(2):227–53 (Aug)PubMedCrossRef Sohar E, Gafni J, Pras M, Heller H (1967) Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 43(2):227–53 (Aug)PubMedCrossRef
3.
go back to reference Lachmann HJ, Sengul B, Yavuzsen TU, Booth DR, Booth SE, Bybee A et al (2006) Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatol (Oxf) 45:746-750 (Feb 9)CrossRef Lachmann HJ, Sengul B, Yavuzsen TU, Booth DR, Booth SE, Bybee A et al (2006) Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatol (Oxf) 45:746-750 (Feb 9)CrossRef
4.
go back to reference Tunca M, Kirkali G, Soyturk M, Akar S, Pepys MB, Hawkins PN (1999) Acute phase response and evolution of familial Mediterranean fever. Lancet 353(9162):1415 (Apr 24)PubMedCrossRef Tunca M, Kirkali G, Soyturk M, Akar S, Pepys MB, Hawkins PN (1999) Acute phase response and evolution of familial Mediterranean fever. Lancet 353(9162):1415 (Apr 24)PubMedCrossRef
5.
go back to reference Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J (1986) Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 314(16):1001–1005 (Apr 17)PubMedCrossRef Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J (1986) Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 314(16):1001–1005 (Apr 17)PubMedCrossRef
6.
go back to reference Bacon PA, Stevens RJ, Carruthers DM, Young SP, Kitas GD (2002) Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun Rev 1(6):338–347 (Dec)PubMedCrossRef Bacon PA, Stevens RJ, Carruthers DM, Young SP, Kitas GD (2002) Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun Rev 1(6):338–347 (Dec)PubMedCrossRef
7.
go back to reference Manzi S, Wasko MC (2000) Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis 59(5):321–325 (May)PubMedCrossRef Manzi S, Wasko MC (2000) Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis 59(5):321–325 (May)PubMedCrossRef
8.
go back to reference Haskard DO (2004) Accelerated atherosclerosis in inflammatory rheumatic diseases. Scand J Rheumatol 33(5):281–292PubMedCrossRef Haskard DO (2004) Accelerated atherosclerosis in inflammatory rheumatic diseases. Scand J Rheumatol 33(5):281–292PubMedCrossRef
9.
go back to reference Peters MJ, Van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34(3):585–592 (Dec)PubMedCrossRef Peters MJ, Van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34(3):585–592 (Dec)PubMedCrossRef
10.
go back to reference Meyer O (2001) Atherosclerosis and connective tissue diseases. Jt Bone Spine 68(6):564–575 (Dec)CrossRef Meyer O (2001) Atherosclerosis and connective tissue diseases. Jt Bone Spine 68(6):564–575 (Dec)CrossRef
11.
go back to reference Poredos P (2004) Intima-media thickness: indicator of cardiovascular risk and measure of the extent of atherosclerosis. Vasc Med 9(1):46–54 (Feb)PubMedCrossRef Poredos P (2004) Intima-media thickness: indicator of cardiovascular risk and measure of the extent of atherosclerosis. Vasc Med 9(1):46–54 (Feb)PubMedCrossRef
12.
go back to reference Raitakari OT, Celermajer DS (2000) Flow-mediated dilatation. Br J Clin Pharmacol 50(5):397–404 (Nov)PubMedCrossRef Raitakari OT, Celermajer DS (2000) Flow-mediated dilatation. Br J Clin Pharmacol 50(5):397–404 (Nov)PubMedCrossRef
13.
go back to reference Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362(6423):801–809 (Apr 29)PubMedCrossRef Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362(6423):801–809 (Apr 29)PubMedCrossRef
14.
go back to reference Van Doornum S, McColl G, Jenkins A, Green DJ, Wicks IP (2003) Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum 48(1):72–80 (Jan)PubMedCrossRef Van Doornum S, McColl G, Jenkins A, Green DJ, Wicks IP (2003) Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum 48(1):72–80 (Jan)PubMedCrossRef
15.
go back to reference Lima DS, Sato EI, Lima VC, Miranda F Jr, Hatta FH (2002) Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 29(2):292–297 (Feb)PubMed Lima DS, Sato EI, Lima VC, Miranda F Jr, Hatta FH (2002) Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 29(2):292–297 (Feb)PubMed
16.
go back to reference Oflaz H, Mercanoglu F, Karaman O, Kamali S, Erer B, Genchellac H et al (2005) Impaired endothelium-dependent flow-mediated dilation in Behçet’s disease: more prominent endothelial dysfunction in patients with vascular involvement. Int J Clin Pract 59(7):777–781 (Jul)PubMedCrossRef Oflaz H, Mercanoglu F, Karaman O, Kamali S, Erer B, Genchellac H et al (2005) Impaired endothelium-dependent flow-mediated dilation in Behçet’s disease: more prominent endothelial dysfunction in patients with vascular involvement. Int J Clin Pract 59(7):777–781 (Jul)PubMedCrossRef
17.
go back to reference Sari I, Okan T, Akar S, Cece H, Altay C, Secil M et al (2006) Impaired endothelial function in patients with ankylosing spondylitis. Rheumatol (Oxf) 45(3):283–286 (Mar)CrossRef Sari I, Okan T, Akar S, Cece H, Altay C, Secil M et al (2006) Impaired endothelial function in patients with ankylosing spondylitis. Rheumatol (Oxf) 45(3):283–286 (Mar)CrossRef
18.
go back to reference Langevitz P, Livneh A, Neumann L, Buskila D, Shemer J, Amolsky D et al (2001) Prevalence of ischemic heart disease in patients with familial Mediterranean fever. Isr Med Assoc J 3(1):9–12 (Jan)PubMed Langevitz P, Livneh A, Neumann L, Buskila D, Shemer J, Amolsky D et al (2001) Prevalence of ischemic heart disease in patients with familial Mediterranean fever. Isr Med Assoc J 3(1):9–12 (Jan)PubMed
19.
go back to reference Akdogan A, Calguneri M, Kalyoncu U, Yavuz B, Karadag O, Aytemir K et al (2005) Endothelium-dependent flow-mediated dilatation is impaired in Familial Mediterranean Fever. Ann Rheum Dis 64(Suppl III):542 Akdogan A, Calguneri M, Kalyoncu U, Yavuz B, Karadag O, Aytemir K et al (2005) Endothelium-dependent flow-mediated dilatation is impaired in Familial Mediterranean Fever. Ann Rheum Dis 64(Suppl III):542
20.
go back to reference Bilginer Y, Basaran C, Ozaltin F, Besbas N, Topaloglu R, Ozen S et al (2006) Long term implications of inflammation in Familial Meditereanean Fever assessed by intima media thickness: a predictor for atherosclerosis?. Ann Rheum Dis 65 (Suppl II):100 Bilginer Y, Basaran C, Ozaltin F, Besbas N, Topaloglu R, Ozen S et al (2006) Long term implications of inflammation in Familial Meditereanean Fever assessed by intima media thickness: a predictor for atherosclerosis?. Ann Rheum Dis 65 (Suppl II):100
21.
go back to reference Seyahi E, Ugurlu S, Cumali R, Balci H, Yazici H, Ozdogan H (2005) Subclinical atherosclerosis in familial Mediterranean fever. Proceedings of the 4th international congress on systemic autoinflammatory diseases “FMF and Beyond”. Bethesda, MD Seyahi E, Ugurlu S, Cumali R, Balci H, Yazici H, Ozdogan H (2005) Subclinical atherosclerosis in familial Mediterranean fever. Proceedings of the 4th international congress on systemic autoinflammatory diseases “FMF and Beyond”. Bethesda, MD
22.
go back to reference Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40(10):1879–1885 (Oct)PubMedCrossRef Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40(10):1879–1885 (Oct)PubMedCrossRef
23.
go back to reference (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20(7):1183–1197 (Jul) (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20(7):1183–1197 (Jul)
24.
go back to reference Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P et al (2000) Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Bmj 321(7255):199–204 (Jul 22)PubMedCrossRef Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P et al (2000) Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Bmj 321(7255):199–204 (Jul 22)PubMedCrossRef
25.
go back to reference Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N et al (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112(21):3337–3347 (Nov 22)PubMedCrossRef Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N et al (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112(21):3337–3347 (Nov 22)PubMedCrossRef
26.
go back to reference Farzaneh-Far A, Roman MJ (2005) Accelerated atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Pract 59(7):823–824 (Jul)PubMedCrossRef Farzaneh-Far A, Roman MJ (2005) Accelerated atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Pract 59(7):823–824 (Jul)PubMedCrossRef
27.
go back to reference Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R et al (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349(25):2399–2406 (Dec 18)PubMedCrossRef Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R et al (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349(25):2399–2406 (Dec 18)PubMedCrossRef
28.
go back to reference Blann AD (2000) Endothelial cell activation, injury, damage and dysfunction: separate entities or mutual terms?. Blood Coagul Fibrinolysis 11(7):623–630 (Oct)PubMedCrossRef Blann AD (2000) Endothelial cell activation, injury, damage and dysfunction: separate entities or mutual terms?. Blood Coagul Fibrinolysis 11(7):623–630 (Oct)PubMedCrossRef
29.
go back to reference Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108(24):2957–2963 (Dec 16)PubMedCrossRef Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108(24):2957–2963 (Dec 16)PubMedCrossRef
30.
go back to reference Van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?. Arthritis Rheum 46(4):862–873 (Apr)PubMedCrossRef Van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?. Arthritis Rheum 46(4):862–873 (Apr)PubMedCrossRef
31.
go back to reference Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, Weissmann G (1995) Colchicine alters the quantitative and qualitative display of selections on endothelial cells and neutrophils. J Clin Invest 96(2):994–1002 (Aug)PubMedCrossRef Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, Weissmann G (1995) Colchicine alters the quantitative and qualitative display of selections on endothelial cells and neutrophils. J Clin Invest 96(2):994–1002 (Aug)PubMedCrossRef
32.
go back to reference Ben-Chetrit E, Bergmann S, Sood R (2006) Mechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis. Rheumatol (Oxf) 45(3):274–282 (Mar)CrossRef Ben-Chetrit E, Bergmann S, Sood R (2006) Mechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis. Rheumatol (Oxf) 45(3):274–282 (Mar)CrossRef
33.
go back to reference Ozcakar ZB, Yalcinkaya F, Yuksel S, Acar B, Gokmen D, Ekim M (2006) Possible effect of subclinical inflammation on daily life in familial Mediterranean fever. Clin Rheumatol 25(2):149–152 (Mar)PubMedCrossRef Ozcakar ZB, Yalcinkaya F, Yuksel S, Acar B, Gokmen D, Ekim M (2006) Possible effect of subclinical inflammation on daily life in familial Mediterranean fever. Clin Rheumatol 25(2):149–152 (Mar)PubMedCrossRef
34.
go back to reference Agewall S (2003) Is impaired flow-mediated dilatation of the brachial artery a cardiovascular risk factor?. Curr Vasc Pharmacol 1(2):107–109 (Jun)PubMedCrossRef Agewall S (2003) Is impaired flow-mediated dilatation of the brachial artery a cardiovascular risk factor?. Curr Vasc Pharmacol 1(2):107–109 (Jun)PubMedCrossRef
35.
go back to reference Berghoff M, Kathpal M, Khan F, Skinner M, Falk R, Freeman R (2003) Endothelial dysfunction precedes C-fiber abnormalities in primary (AL) amyloidosis. Annals of neurology 53(6):725–730 (Jun)PubMedCrossRef Berghoff M, Kathpal M, Khan F, Skinner M, Falk R, Freeman R (2003) Endothelial dysfunction precedes C-fiber abnormalities in primary (AL) amyloidosis. Annals of neurology 53(6):725–730 (Jun)PubMedCrossRef
36.
go back to reference Bozkurt AI, Sahinoz S, Ozcirpici B, Ozgur S, Sahinoz T, Acemoglu H et al (2006) Patterns of active and passive smoking, and associated factors, in the South-east Anatolian Project (SEAP) region in Turkey. BMC public health 6:15PubMedCrossRef Bozkurt AI, Sahinoz S, Ozcirpici B, Ozgur S, Sahinoz T, Acemoglu H et al (2006) Patterns of active and passive smoking, and associated factors, in the South-east Anatolian Project (SEAP) region in Turkey. BMC public health 6:15PubMedCrossRef
Metadata
Title
Early ultrasonographic markers of atherosclerosis in patients with familial Mediterranean fever
Authors
Ismail Sari
Oguzhan Karaoglu
Gercek Can
Servet Akar
Aytac Gulcu
Merih Birlik
Nurullah Akkoc
Mehmet Tunca
Yigit Goktay
Fatos Onen
Publication date
01-09-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 9/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0529-2

Other articles of this Issue 9/2007

Clinical Rheumatology 9/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.